IP Library Granted Patent US 9,295,691
Granted Patent B2
US 9,295,691 · App. 14/200,915 · Granted Mar 29, 2016

Method for repairing or replacing damaged tissue

Inventor: Ayman Boutros (Great Falls, VA)
A61K31/78A61K31/765A61K45/06A61K47/32A61L27/16A61L27/20A61L27/34A61L27/48A61L27/52A61L27/54A61L27/58A61L2300/402A61L2300/41A61L2400/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,295,691
App. No.
14/200,915
Granted
Mar 29, 2016
Kind
B2
Abstract

A method for repairing or replacing damaged tissue, or for providing post-surgical augmentation, comprising administering a pliable biocompatible material and a physiologically acceptable suspending agent to a patient is disclosed. Copolymers of unsubstituted acrylate and substituted acrylate are disclosed as pliable biocompatible materials.

Claims (19)

1. A method of preparing a composition for repairing or replacing tissue comprising admixing a finely ground copolymer of phenylethyl acrylate and phenylethyl methacrylate with a physiologically acceptable suspending agent to form an injectable, biocompatible material.

2. The method of claim 1 , wherein the copolymer is a powder, a non-porous microbead, or a microsphere.

3. The method of claim 1 , wherein the copolymer is in the form of particles each having a diameter selected from the group consisting of: about 10 μm to about 100 μm; about 0.01 μm to about 10 μm, and about 0.01 μm to about 5 μm.

4. The method of claim 1 , wherein the physiologically acceptable suspending agent is resorbable.

5. The method of claim 1 , wherein the physiologically acceptable suspending agent is selected from the group consisting of a buffered physiological solution, cross-linked sodium hyaluronate, a non cross-linked sodium hyaluronate, collagen, and any combination thereof.

6. The method of claim 1 , wherein the molar ratio between the phenylethyl acrylate and the phenylethyl methacrylate is selected from the group consisting of: between about 1:1000 and about 1:1; between about 1:10 and about 1:1; between about 1:1000 and about 1:10; about 1:1000; about 1:100; about 1:10; about 1:9; about 1:8; about 1:7; about 1:6; about 1:5; about 1:4; about 1:3; about 1:2; about 1:1; between about 10:1 and about 1:1; between about 1000:1 and about 10:1; about 100:1; about 10:1; about 9:1; about 8:1; about 7:1; about 6:1; about 5:1; about 4:1; about 3:1; about 2:1; about 1:2; about 3:2; about 5:2; about 1:3; about 2:3; about 4:3; about 5:3; about 1:4; about 3:4; about 5:4; about 1:5; about 2:5; about 3:5; about 4:5; about 2:1; about 2:3; about 2:5; about 3:1; about 3:2; about 3:4; about 3:5; about 4:1; about 4:3; about 4:5; about 5:1; about 5:2; about 5:3; and about 5:4.

7. The method of claim 1 , wherein said copolymer is cross-linked with 1.4 butanediol diacrylate.

8. A method of preparing a soft tissue filler for repairing or replacing tissue comprising admixing an acrylate/methacrylate copolymer with a physiologically acceptable suspending agent to form an injectable, biocompatible material.

9. The method of claim 8 , wherein the acrylate/methacrylate copolymer is a finely ground solid.

10. The method of claim 9 , wherein the finely ground solid is a powder.

11. The method of claim 9 , wherein the finely ground solid is a non-porous microbead.

12. The method of claim 9 , wherein the finely ground solid is a microsphere.

13. The method of claim 9 , wherein the finely ground solid has a diameter of from about less than 0.1 μm to about 10 μm.

14. The method of claim 9 , wherein the physiologically acceptable suspending agent is resorbable.

15. The method of claim 9 , wherein the physiologically acceptable suspending agent is a buffered physiological solution.

16. The method of claim 9 , wherein the physiologically acceptable suspending agent comprises cross-linked sodium hyaluronate.

17. The method of claim 9 , wherein the physiologically acceptable suspending agent comprises a non cross-linked sodium hyaluronate.

18. The method of claim 9 , wherein the physiologically acceptable suspending agent comprises collagen.

19. The method of claim 18 , wherein the collagen is derived from natural sources or is synthetic.

Continuity (4)
Division 13336340 · Dec 23, 2011
Continuation In Part 12741280
Continuation In Part 11926930 · Oct 29, 2007
Related Publication 20140186418A1 · Jul 3, 2014